Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BIAL, Recipharm Expand Long-Term API Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

BIAL, Recipharm Expand Long-Term API Supply Pact

Expanded agreement follows approval and launch of Opicapone in Japan to treat Parkinson’s.

By: Contract Pharma

Contract Pharma Staff

BIAL, a Portuguese pharma company, and Recipharm have expanded a long-term agreement for the global manufacture and supply of BIAL’s proprietary molecule opicapone.

The API being manufactured at Recipharm’s facility in Cramlington, UK is used to formulate BIAL’s Ongentys product, an adjunctive therapy used to treat patients with Parkinson’s disease.

The expansion of the agreement with BIAL follows the successful market authorization application in Japan, with the product launch on August 26, 2020.

The new agreement provides both companies with a long-term partnership that will ensure continued supply. Opicapone (Ongentys) is approved in Europe, U.S., South Korea, Taiwan, Australia and Japan.

Bernard Pluta, President, Development Services at Recipharm, said, “We have worked for several years with process development and scale up to commercial scale of the manufacturing of opicapone. The approval in Japan marks a significant milestone for this important product for patients suffering Parkinson’s disease and we look forward to continue to work together with BIAL to supply opicapone to Japan and elsewhere.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics